Results 131 to 140 of about 57,585 (206)

Characterization of Phylogroups, Virulence Factors and Antimicrobial Resistance in Canine Pyometra‐associated Escherichia coli

Veterinary Medicine and Science, Volume 12, Issue 5, September 2026.
This study characterized 56 Escherichia coli isolates obtained from canine pyometra, which predominantly belonged to phylogroup B2 and harboured multiple virulence genes, with high multidrug resistance rates indicating potential clinical and zoonotic risks. ABSTRACT The presence of multidrug‐resistant extraintestinal pathogenic Escherichia coli (ExPEC)
İnci Başak Müştak, Murat Onur Yazlık, Beyza Nur Şitvan, Hamit Kaan Müştak, Ufuk Kaya   +4 more
wiley   +1 more source

The sublingual vaccine MV140 is dominant over prophylactic antibiotics for the prevention of recurrent, uncomplicated urinary tract infections in adult women A cost-utility analysis. [PDF]

Can Urol Assoc J
Doiron RC, Nickel JC, Kamdar S.
europepmc   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

American Journal of Hematology, Volume 101, Issue 8, Page 1928-1937, August 2026.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung‐Yu Huang, Rakesh Popat, Joaquín Martínez‐Lopez, Efsthathios Kastritis, Wee‐Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin, Nadine Abdullah, Niels Abildgaard, Ingerid Abrahamsen, Melissa Alsina, Kenneth Anderson, Hervé Avet‐Loiseau, Ashraf Badros, Nizar Jacques Bahlis, Susan Bal, Rahul Banerjee, Dina Ben‐Yehuda, Jesús G. Berdeja, Michele Cavo, Ajai Chari, Wen‐Ming Chen, Marta Chesi, Wee‐Joo Chng, Yael Cohen, Adam Cohen, Gordon Cook, Luciano Costa, Andrew Cowan, Carlos Fernández de Larrea, Benjamin Derman, Juan Du, Hermann Einsele, Gösta Gahrton, Francesca Gay, Sergio A. Giralt, Simon Harrison, J Jean‐Luc Harousseau, Joy Ho, Doris Hansen, Maung Myo Htut, Andrzej J. Jakubowiak, Murali Janakiram, Prashant Kapoor, Efstathios Kastritis, Jonathan Kaufman, Kihyun Kim, Amrita Krishnan, Shaji Kumar, Chara Kyriakou, Xavier Leleu, Yi Lin, Sagar Lonial, Matthew frigault, Johan L. Lund, Elias Mai, Angelo Maiolino, Elias Mai, Angelo Maiolino, Sireesha Asoori Maringanti, Thomas Martin, Joaquin Martinez‐Lopez, María‐Victoria Mateos, Giampaolo Merlini, Hira Mian, Joseph Mikhael, Monique Minnema, Philippe Moreau, Gareth Morgan, Nikhil Munshi, Omar Nadeem, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Rimke Oostvogel, Alberto Orfao, Paula Rodriguez Otero, Darren Pan, Krina Patel, Rashesh Popat, Noemí Puig   +94 more
wiley   +1 more source

Diabetes and hyperglucosuria exacerbate the severity of urinary tract infection caused by uropathogenic <i>E</i>. <i>coli</i> in the mouse model. [PDF]

Infect Immun
Neupane S, George I, Vanitshavit V, Hejtmancik T, Kim DM, Wright G, Adams LG, Subashchandrabose S.   +7 more
europepmc   +1 more source

A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION ABBV‐916, an anti‐amyloid immunotherapy, was evaluated in patients with early Alzheimer's disease (AD). METHODS This phase 1b/2, double‐blind, placebo‐controlled study consisted of two stages: multiple ascending dose (Stage A) and dose expansion (Stage B).
Shau Yu Lynch, Yamin Wang, Deli Wang, Sagar S Bachhav, Hao Xiong, Joey Boiser, Edwin Stage, Anthony W Bannon, Ole Graff, Hana Florian   +9 more
wiley   +1 more source

Calprotectin as a Diagnostic Marker for Lower Respiratory Tract Infection and Sepsis in the Emergency Department. [PDF]

Open Forum Infect Dis
Wollmer M, Wessman T, Melander O, Larsson A, Ruge T.   +4 more
europepmc   +1 more source

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2465-2473, August 2026.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

Neither tranexamic acid nor ulinastatin affects the activated clotting time values in healthy volunteers and heparinized cardiovascular surgery patients. [PDF]

J Cardiothorac Surg
Jia B, Deng J, Yao Y, Evidence in Cardiovascular Anesthesia Group.   +3 more
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2741-2755, August 2026.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Diagnostic tests for urinary tract infections and antimicrobial resistance-a reality check between diagnostic innovation and implementation: a critical narrative review. [PDF]

Front Cell Infect Microbiol
Mohan V, Mitsakakis K.
europepmc   +1 more source